<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine <z:chebi fb="0" ids="50266">prodrug</z:chebi>, plus irinotecan in previously untreated patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Between April 2004 and February 2005, 41 patients with previously untreated advanced or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> were enrolled in the study </plain></SENT>
<SENT sid="2" pm="."><plain>Chemotherapy consisted of oral administration in S-1 at 40 mg/m(2) twice daily on days 1 to 14 and intravenous infusion of irinotecan at 150 mg/m(2) on day 1 in a 21-day cycle </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The median patient follow-up was 78.0 months </plain></SENT>
<SENT sid="4" pm="."><plain>The median survival time was 23.7 months, and the 2-year survival rate was 50% </plain></SENT>
<SENT sid="5" pm="."><plain>The median time to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> was 8.3 months </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The results of this long-term update confirmed that first-line combination therapy with oral S-1 plus irinotecan was effective in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
</text></document>